Interferon-γ-induced necrosis: An antitumor biotherapeutic perspective

Journal of Interferon and Cytokine Research

Volumn 33, Issue 4, 2013, Pages 171-180

  Balachandran, Siddharth ^a   Adams, Gregory P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; MANGANESE SUPEROXIDE DISMUTASE; SUNITINIB; TEMSIROLIMUS; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LOW DRUG DOSE; MONOTHERAPY; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION INITIATION; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-GAMMA; KIDNEY NEOPLASMS; NECROSIS; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; RECOMBINANT FUSION PROTEINS; RNA-BINDING PROTEINS;

EID: 84876114298     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0087     Document Type: Review

References (99)

1. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. 1990. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod 9(5):522-527.
2. An J, Fisher M, Rettig MB. 2005. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NFkappaB- dependent mechanism. Oncogene 24(9):1563-1570.
3. An J, Rettig MB. 2005. Mechanism of von Hippel-Lindau protein- mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 25(17):7546-7556.
4. An J, Rettig MB. 2007. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6(1):61-69.
5. An J, Sun Y, FisherM, RettigMB. 2004.Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther 3(6):727-736.
6. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. 2001. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng 14(8):529-532.
7. Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C. 1989. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7(12):1875-1884.
8. Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN. 2000. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol 74(3):1513-1523.
9. Balachandran S, Thomas E, Barber GN. 2004. A FADD-dependent innate immune mechanism in mammalian cells. Nature 432(7015):401-405.
10. Basagoudanavar SH, Thapa RJ, Nogusa S, Wang J, Beg AA, Balachandran S. 2011. Distinct roles for the NF-kappa B RelA subunit during antiviral innate immune responses. J Virol 85(6):2599-2610.
11. Baud V, Karin M. 2009. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33-40.
12. Beg AA, Baltimore D. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274(5288):782-784.
13. Ben-Neriah Y, Karin M. 2011. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12(8):715-723.
14. Bennett CL, Vogelzang NJ, Ratain MJ, Reich SD. 1986. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep 70(9):1081-1084.
15. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990.
16. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. 2006. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112(2):358-404.
17. Boursalian TE, McEarchern JA, Law CL, Grewal IS. 2009. Targeting CD70 for human therapeutic use. Adv Exp Med Biol 647:108-119.
18. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. 2010. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res 8(5):729- 738.
19. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. 2006. The NF-kappaB-mediated control of ROS and JNK signaling. Histol Histopathol 21(1):69-80.
20. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. 2011. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11(3):239-253.
21. Chen DY, Uzzo RG. 2011. Evaluation and management of the renal mass. Med Clin North Am 95(1):179-189.
22. Chen G, Goeddel DV. 2002. TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634-1635.
23. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. 2005. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1):CD001425.
24. Cvek B, Dvorak Z. 2011. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr Pharm Des 17(15):1483-1499.
25. D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W, Lewis JL, Jr. 1988. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6(4):689-695.
26. Deb A, Haque SJ, Mogensen T, Silverman RH, Williams BR. 2001. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol 166(10):6170-6180.
27. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. 1995. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferoninduced cell death. Genes Dev 9(1):15-30.
28. Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J, von Eggeling F. 2005. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 41(12):1794-1801.
29. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D. 2005. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116(2):304-313.
30. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. 1994. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 152(3):841-845.
31. Foon KA, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK, Herberman RB. 1985. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 20(3):193-197.
32. Garnick MB, Reich SD, Maxwell B, Coval-Goldsmith S, Richie JP, Rudnick SA. 1988. Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 139(2):251-255.
33. Ghetie V, Ward ES. 2002. Transcytosis and catabolism of antibody. Immunol Res 25(2):97-113.
34. Gilmore TD. 2006. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25(51):6680-6684.
35. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A. 1998. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338(18):1265-1271.
36. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. 2008. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6):435-446.
37. Greer SN, Metcalf JL, Wang Y, Ohh M. 2012. The updated biology of hypoxia-inducible factor. EMBO J 31(11):2448-2460.
38. Hayden MS, Ghosh S. 2004. Signaling to NF-kappaB. Genes Dev 18(18):2195-2224.
39. Hayden MS, Ghosh S. 2008. Shared principles in NF-kappaB signaling. Cell 132(3):344-362.
40. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J. 2008. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135(7):1311-1323.
41. Hudes GR. 2009. Targeting mTOR in renal cell carcinoma. Cancer 115(10 Suppl):2313-2320.
42. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300.
43. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. 1994. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 12(11):2321-2326.
44. Jones PL, Ping D, Boss JM. 1997. Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-beta and NF-kappaB. Mol Cell Biol 17(12): 6970-6981.
45. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J. 2005. CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173(6):2150-2153.
46. Kaelin WG, Jr. 2008. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865-873.
47. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. 2003. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1(3):E83.
48. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B. 1997. The Heidelberg classification of renal cell tumours. J Pathol 183(2):131-133.
49. Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE. 2009. Mitochondria and reactive oxygen species. Free Radic Biol Med 47(4):333-343.
50. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU. 1985. Pharmacokinetics, singledose tolerance, and biological activity of recombinant gammainterferon in cancer patients. Cancer Res 45(6):2866-2872.
51. Lane HC, Davey RT, Jr., Sherwin SA, Masur H, Rook AH, Manischewitz JF, Quinnan GV, Smith PD, Easter ME, Fauci AS. 1989. A phase I trial of recombinant human interferongamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 9(4):351-361.
52. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF. 2006. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66(4):2328-2337.
53. Linehan WM, Srinivasan R, Schmidt LS. 2010. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277- 285.
54. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. 2011. The epidemiology of renal cell carcinoma. Eur Urol 60(4):615-621.
55. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. 2007. Interferon: cellular executioner or white knight? Curr Med Chem 14(12):1279-1289.
56. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440(7081):228-232.
57. Mathupala SP, Ko YH, Pedersen PL. 2010. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797(6-7):1225-1230.
58. Miller CH, Maher SG, Young HA. 2009. Clinical use of interferon- gamma. Ann N Y Acad Sci 1182:69-79.
59. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. 2003. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics 22(4):197-207.
60. Moreno-Sanchez R, Rodriguez-Enriquez S, Saavedra E, Marin- Hernandez A, Gallardo-Perez JC. 2009. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors 35(2):209-225.
61. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. 2002. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289-296.
62. MRCCC. 1999. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146):14-17.
63. Muss HB, Caponera M, Zekan PJ, Jackson DV, Jr., Stuart JJ, Richards F, Cooper MR, Levin EA, Reich SD, Capizzi RL. 1986. Recombinant gamma interferon in advanced breast cancer: a phase II trial. Invest New Drugs 4(4):377-381.
64. Nyhan MJ, O'Sullivan GC, McKenna SL. 2008. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 36(Pt 3):472-478.
65. Otto U, Conrad S, Schneider AW, Klosterhalfen H. 1988. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial. Arzneimittelforschung 38(11):1658-1660.
66. Pal SK, Figlin RA. 2010. Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol 5(2):131-138.
67. Pasche N, Neri D. 2012. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17(11-12): 583-590.
68. Pfeffer LM. 2011. The role of nuclear factor kappaB in the interferon response. J Interferon Cytokine Res 31(7):553-559.
69. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G. 2004. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119(4):529-542.
70. Pirrotta MT, Bernardeschi P, Fiorentini G. 2011. Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 18(11): 1651-1657.
71. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat Rev Immunol 5(5):375-386.
72. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. 1987. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 6(1): 20-27.
73. Ramsay EE, Hogg PJ, Dilda PJ. 2011. Mitochondrial metabolism inhibitors for cancer therapy. Pharm Res 28(11):2731-2744.
74. Rinehart JJ, Malspeis L, Young D, Neidhart JA. 1986. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. J Biol Response Mod 5(4):300-308.
75. Rodriguez-Enriquez S, Gallardo-Perez JC, Marin-Hernandez A, Aguilar-Ponce JL, Mandujano-Tinoco EA, Meneses A, Moreno- Sanchez R. 2011. Oxidative phosphorylation as a target to arrest malignant neoplasias. Curr Med Chem 18(21):3156- 3167.
76. Roos FC, Roberts AM, Hwang II, Moriyama EH, Evans AJ, Sybingco S, Watson IR, Carneiro LA, Gedye C, Girardin SE, Ailles LE, Jewett MA, Milosevic M, Wilson BC, Bell JC, Der SD, Ohh M. 2010. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med 2(7): 275-288.
77. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, Piao JH, Yagita H, Okumura K, Doi T, Nakano H. 2003. NFkappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22(15):3898-909.
78. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ. 2008. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100(9):649-662.
79. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. 2002. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics 21(6): 421-432.
80. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
81. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. 1997. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80(5):987-989.
82. Sufan RI, Jewett MA, Ohh M. 2004. The role of von Hippel- Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 287(1):F1-F6.
83. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X. 2012. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148(1-2):213-227.
84. Taniguchi T, Takaoka A. 2002. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14(1):111-116.
85. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, Beg AA, Madesh M, Balachandran S. 2011. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol 31(14):2934-2946.
86. Theil EC. 1987. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 56:289-315.
87. Trautmann A. 2009. Extracellular ATP in the immune system: more than just a danger signal. Sci Signal 2(56):pe6.
88. Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. 1986. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 4(2):137-146.
89. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. 2010. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11(10):700-714.
90. Wang Z, Jiang H, Chen S, Du F, Wang X. 2012. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 148(1-2):228-243.
91. Weiner LM, Surana R, Wang S. 2010. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327.
92. Wirth MP. 1993. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20(2):283-295.
93. Xiang J, Qi Y, Cook D, Moyana T. 1996. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Hum Antibodies Hybridomas 7(1):2-10.
94. Xiang J, Qi Y, Luo X, Liu E. 1993. Recombinant bifunctional molecule FV/IFN-gamma possesses the anti-tumor FV as well as the gamma interferon activities. Cancer Biother 8(4):327- 337.
95. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, KimWY, Olumi AF, KaelinWG, Jr. 2007. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28(1): 15-27.
96. Yoshida T, Okazaki N, Yoshino M, Okhura H, Shimada Y. 1990. Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer 26(4): 545-546.
97. Younes HM, Amsden BG. 2002. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J Pharm Sci 91(1):2-17.
98. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. 2009. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325(5938):332-336.
99. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu ZG. 2012. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A 109(14):5322-5327.